In addition, accumulation of PD1 + CD8 + T cells was observed in the liver of NASH patients, which may lead to tissue damage and impaired immune monitoring and reduce the responsiveness of NASH-HCC patients to PD-1/PD-L1 immunotherapy [199]. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatohepatitis.